Zinplava receives FDA approval to reduce recurrence of Clostridium difficile infection

Merck announced that the U.S. Food and Drug Administration (FDA) has approved ZINPLAVAa (bezlotoxumab) Injection 25 mg/mL. Merck anticipates making ZINPLAVA available in first quarter 2017. ZINPLAVA is indicated to reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older who are receiving antibacterial drug treatment of CDI and are at ["]